Frederick Montgomery

Fred Montgomery has spent the last 25 years developing and patenting NO delivery system technology leading to the commercialization of nitric oxide therapy. He led the development of the INOvent delivery system for Datex-Ohmeda, which in 1999 was the first FDA 510(k) cleared nitric oxide delivery system that led to the commercial marketing of INO Therapy in the year 2000. He established the Medical Device Group at INO Therapeutics which developed the INOmax DS and DSIR products, the leading NO delivery systems in the United States to this day. Mr. Montgomery left Ikaria (formerly INO Therapeutics) in 2011 and co-founded NitricGen Inc. He received his Doctor of Philosophy degree from the University of Salford, England and his Master’s of Business Administration from the University of Bradford, England.